https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/counts-individuals-gout-using-urate-lowering-therapy-ult-and
Counts of Individuals with Gout Using Urate-Lowering Therapy (ULT) and Switching between ULT Products: A Descriptive Analysis
Modular Programs
11/12/2020
Modular Programs
11/12/2020
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/risk-cardiac-congenital-malformations-following-0
Risk of Cardiac Congenital Malformations Following Armodafinil or Modafinil Use: A Descriptive Analysis
Modular Programs
11/17/2020
Modular Programs
11/17/2020
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/risk-cardiac-congenital-malformations-following-armodafinil
Risk of Cardiac Congenital Malformations Following Armodafinil or Modafinil Use: A Propensity Score Matched Analysis
Modular Programs
11/17/2020
Modular Programs
11/17/2020
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/ustekinumab-dispensing-patterns-descriptive-analysis
Ustekinumab Dispensing Patterns: A Descriptive Analysis
Analyses
11/24/2020
Analyses
11/24/2020
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/serious-infections-among-immunocompromised-health-plan
Serious Infections among Immunocompromised Health Plan Members
Modular Programs
02/24/2021
Modular Programs
02/24/2021
https://sentinelinitiative.org/methods-data-tools/methods/covid-19-pregnancy-study-implementation
COVID-19 Pregnancy Study Implementation
Methods, Data, & Tools
02/24/2021
Methods, Data, & Tools
02/24/2021
https://sentinelinitiative.org/methods-data-tools/methods/advancing-scalable-natural-language-processing-approaches-unstructured
Advancing Scalable Natural Language Processing Approaches for Unstructured Electronic Health Record Data
Methods, Data, & Tools
02/26/2021
Methods, Data, & Tools
02/26/2021
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/pregnancy-among-women-heart-failure-descriptive-analysis
Pregnancy among Women with Heart Failure: A Descriptive Analysis
Modular Programs
03/07/2021
Modular Programs
03/07/2021
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/characterization-mothers-mother-infant-linkage-table
Characterization of Mothers in the Mother-Infant Linkage Table in the Sentinel Distributed Database: A Descriptive Analysis
Modular Programs
03/11/2021
Modular Programs
03/11/2021
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/counts-individuals-sentinel-distributed-database
Counts of Individuals in the Sentinel Distributed Database
Modular Programs
03/22/2021
Modular Programs
03/22/2021
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/venous-and-arterial-thromboembolism-among-new-users-nuvaring
Venous and Arterial Thromboembolism among New Users of NuvaRing and Other Combined Hormonal Contraceptives: A Descriptive Analysis
Modular Programs
03/25/2021
Modular Programs
03/25/2021
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/angioedema-following-dipeptidyl-peptidase-iv-dpp-iv
Angioedema following Dipeptidyl Peptidase IV (DPP IV) Inhibitors and Angiotensin Converting Enzyme (ACE) Inhibitors Use: A Descriptive Analysis
Modular Programs
03/26/2021
Modular Programs
03/26/2021
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/follow-time-guselkumab-risankizumab-and-tildrakizumab-users
Follow-Up Time for Guselkumab, Risankizumab, and Tildrakizumab Users with Plaque Psoriasis: A Descriptive Analysis
Modular Programs
03/30/2021
Modular Programs
03/30/2021
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2016
Duration of Follow Up for New Molecular Entities Approved in 2016
Analyses
04/16/2021
Analyses
04/16/2021
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2014-and
Duration of Follow Up for New Molecular Entities Approved in 2014 and 2015
Analyses
04/16/2021
Analyses
04/16/2021
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2010-2012
Duration of Follow Up for New Molecular Entities Approved in 2010, 2012, and 2013
Analyses
04/16/2021
Analyses
04/16/2021
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2008-and
Duration of Follow Up for New Molecular Entities Approved in 2008 and 2009
Analyses
04/16/2021
Analyses
04/16/2021
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2005-2006
Duration of Follow Up for New Molecular Entities Approved in 2005, 2006, and 2007
Analyses
04/16/2021
Analyses
04/16/2021
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2011
Duration of Follow Up for New Molecular Entities Approved in 2011
Analyses
04/16/2021
Analyses
04/16/2021
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/patterns-insulin-product-use-and-billing-codes-descriptive
Patterns in Insulin Product Use and Billing Codes: A Descriptive Analysis
Modular Programs
04/16/2021
Modular Programs
04/16/2021
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-sacubitrilvalsartan-descriptive-analysis
Utilization of Sacubitril/Valsartan: A Descriptive Analysis
Modular Programs
04/19/2021
Modular Programs
04/19/2021
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/incidence-rate-severe-uterine-bleeding-among-new-users-oral
Incidence Rate of Severe Uterine Bleeding Among New Users of Oral Anticoagulants: A Descriptive Analysis
Modular Programs
05/18/2021
Modular Programs
05/18/2021
https://sentinelinitiative.org/methods-data-tools/methods/treescan-pregnancy
TreeScan in Pregnancy
Methods, Data, & Tools
07/14/2021
Methods, Data, & Tools
07/14/2021
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/brand-and-generic-tacrolimus-use-following-kidney-heart-and
Brand and Generic Tacrolimus Use following Kidney, Heart, and Liver Transplants: A Descriptive Analysis
Modular Programs
08/11/2021
Modular Programs
08/11/2021
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2017
Duration of Follow Up for New Molecular Entities Approved in 2017: A Descriptive Analysis
Analyses
08/13/2021
Analyses
08/13/2021
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-drugs-approved-risk-evaluation-and-mitigation
Utilization of Drugs with Approved Risk Evaluation and Mitigation Strategies (REMS) that Employ Elements to Assure Safe Use (ETASU)
Assessments
08/23/2021
Assessments
08/23/2021
https://sentinelinitiative.org/methods-data-tools/methods/making-medicaid-data-more-accessible-through-common-data-models-and-fhir
Making Medicaid Data More Accessible Through Common Data Models and FHIR APIs
Methods, Data, & Tools
09/24/2021
Methods, Data, & Tools
09/24/2021
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/oral-metoclopramide-use-descriptive-analysis
Oral Metoclopramide Use: A Descriptive Analysis
Modular Programs
09/30/2021
Modular Programs
09/30/2021
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/use-multiple-sclerosis-drugs-among-pregnant-women-live-birth
Use of Multiple Sclerosis Drugs Among Pregnant Women with Live-Birth Deliveries: A Descriptive Analysis
Assessments
10/20/2021
Assessments
10/20/2021
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/racial-differences-covid-19-outcomes-2020-2021
Racial Differences in COVID-19 Outcomes (2020-2021)
Assessments
12/08/2021
Assessments
12/08/2021
https://sentinelinitiative.org/methods-data-tools/methods/development-and-illustration-framework-conducting-nonrandomized-studies
Development and Illustration of a Framework for Conducting Nonrandomized Studies of Medication Safety and Effectiveness Using Healthcare Databases
Methods, Data, & Tools
12/10/2021
Methods, Data, & Tools
12/10/2021
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/intentional-self-harm-and-hospitalized-depression-following
Intentional Self-Harm and Hospitalized Depression Following Sertraline Use: A Propensity Score Matched Analysis
Analyses
12/15/2021
Analyses
12/15/2021
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/intentional-self-harm-and-hospitalized-depression-0
Intentional Self-Harm and Hospitalized Depression Following Sertraline Use: A Propensity Score Matched Analysis (A Follow-up to a Previous Analysis)
Analyses
12/15/2021
Analyses
12/15/2021
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2017-updated
Duration of Follow Up for New Molecular Entities Approved in 2017: An Updated Descriptive Analysis
Analyses
01/21/2022
Analyses
01/21/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2019
Duration of Follow Up for New Molecular Entities Approved in 2019: A Descriptive Analysis
Analyses
01/26/2022
Analyses
01/26/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/n-nitrosodimethylamine-ndma-contaminated-and-non-ndma
N‐nitrosodimethylamine (NDMA)‐Contaminated and Non‐NDMA‐Contaminated Valsartan Use: A Descriptive Analysis
Analyses
02/18/2022
Analyses
02/18/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/tofacitinib-disease-modifying-anti-rheumatic-drugs-dmards
Tofacitinib, Disease-Modifying Anti-Rheumatic Drugs (DMARDs) and Tumor Necrosis Factor Inhibitors (TNFi) Use: A Descriptive Analysis
Analyses
02/24/2022
Analyses
02/24/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/bleeding-events-and-venous-thromboembolism-vte-following
Bleeding Events and Venous Thromboembolism (VTE) following Enoxaparin Use: A Descriptive Analysis
Analyses
02/25/2022
Analyses
02/25/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/incidence-and-prevalence-n-nitrosodimethylamine-ndma-and-n
Incidence and Prevalence of N-Nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA) Contaminated Valsartan Use: A Descriptive Analysis
Analyses
03/01/2022
Analyses
03/01/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/mometasone-furoate-sinus-implant-use-patients-nasal-polyps
Mometasone Furoate Sinus Implant Use in Patients with Nasal Polyps: A Descriptive Analysis
Analyses
03/03/2022
Analyses
03/03/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/human-epidermal-growth-factor-receptor-2-her2-antagonist-use
Human Epidermal Growth Factor Receptor 2 (HER2) Antagonist Use in Patients with Live Birth Deliveries: A Descriptive Analysis
Analyses
03/11/2022
Analyses
03/11/2022
https://sentinelinitiative.org/methods-data-tools/methods/augmenting-date-death-cause-death-ascertainment-sentinel
Augmenting Date of Death & Cause of Death Ascertainment in Sentinel
Methods, Data, & Tools
03/16/2022
Methods, Data, & Tools
03/16/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/incident-and-prevalent-use-loop-diuretics-descriptive
Incident and Prevalent Use of Loop Diuretics: A Descriptive Analysis
Analyses
03/23/2022
Analyses
03/23/2022
https://sentinelinitiative.org/engage-sentinel/quarterly-newsletter
Quarterly Newsletter
Spotlight
03/24/2022
Spotlight
03/24/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/valganciclovir-use-children-congenital-cytomegalovirus
Valganciclovir Use in Children with Congenital Cytomegalovirus Disease (cCMV) or Cytomegalovirus (CMV) Infection: A Descriptive Analysis
Analyses
03/25/2022
Analyses
03/25/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/epidiolex-prescription-cannabidiol-utilization-patterns
Epidiolex (prescription cannabidiol) Utilization Patterns: A Descriptive Analysis
Analyses
03/28/2022
Analyses
03/28/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/hydroxyurea-use-among-patients-sickle-cell-disease-scd
Hydroxyurea Use Among Patients with Sickle Cell Disease (SCD): A Descriptive Analysis
Analyses
03/29/2022
Analyses
03/29/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/estimated-prevalence-glomerular-diseases-descriptive
Estimated Prevalence of Glomerular Diseases: A Descriptive Analysis
Analyses
03/29/2022
Analyses
03/29/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/estimated-prevalence-glomerular-diseases-updated-descriptive
Estimated Prevalence of Glomerular Diseases: An Updated Descriptive Analysis
Analyses
03/29/2022
Analyses
03/29/2022
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/saphnelo-anifrolumab-fnia
Assessment of ARIA Sufficiency: Saphnelo (anifrolumab-fnia)
Sufficiency Assessments
04/01/2022
Sufficiency Assessments
04/01/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-brodalumab-descriptive-analysis
Utilization of Brodalumab: A Descriptive Analysis
Analyses
04/05/2022
Analyses
04/05/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/counts-and-characteristics-individuals-drug-device
Counts and Characteristics of Individuals With Drug-Device Combination Use: A Descriptive Analysis
Analyses
04/18/2022
Analyses
04/18/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2018
Duration of Follow Up for New Molecular Entities Approved in 2018: A Descriptive Analysis
Analyses
04/20/2022
Analyses
04/20/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/incidence-and-prevalence-confounding-variables-over-time
Incidence and Prevalence of Confounding Variables Over Time in the Sentinel Distributed Database (SDD): A Descriptive Analysis
Analyses
04/21/2022
Analyses
04/21/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/thromboembolic-stroke-major-extracranial-bleeding-0
Thromboembolic Stroke, Major Extracranial Bleeding, Gastrointestinal Bleeding, and Intracranial Hemorrhage following Direct Oral Anticoagulant Use: An Inverse Probability of Treatment Weighting Analysis
Analyses
04/25/2022
Analyses
04/25/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/death-data-exploration-descriptive-analysis
Death Data Exploration: A Descriptive Analysis
Analyses
04/28/2022
Analyses
04/28/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/characterization-pediatric-demographics-and-enrollment
Characterization of Pediatric Demographics and Enrollment in the Sentinel Distributed Database: A Descriptive Analysis
Analyses
05/16/2022
Analyses
05/16/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/serious-infection-following-ustekinumab-use-patients-crohn-s
Serious Infection Following Ustekinumab Use in Patients with Crohn’s Disease or Ulcerative Colitis: A Descriptive Analysis
Analyses
05/17/2022
Analyses
05/17/2022
https://sentinelinitiative.org/methods-data-tools/methods/approaches-handling-partially-observed-confounder-data-electronic-health
Approaches to Handling Partially Observed Confounder Data From Electronic Health Records (EHR) In Non-randomized Studies of Medication Outcomes
Methods, Data, & Tools
06/01/2022
Methods, Data, & Tools
06/01/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/outpatient-corticosteroid-use-patients-covid-19-descriptive
Outpatient Corticosteroid Use in Patients With COVID-19: A Descriptive Analysis
Analyses
06/01/2022
Analyses
06/01/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/outpatient-corticosteroid-use-patients-covid-19-updated
Outpatient Corticosteroid Use in Patients With COVID-19: An Updated Descriptive Analysis
Analyses
06/02/2022
Analyses
06/02/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/bamlanivimab-bamlanivimab-and-etesevimab-and-casirivimab
Bamlanivimab, Bamlanivimab and Etesevimab, and Casirivimab-Imdevimab Use in Patients with COVID-19: A Descriptive Analysis
Analyses
06/14/2022
Analyses
06/14/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/characterizing-pregnant-women-and-without-evidence-heart
Characterizing Pregnant Women With and Without Evidence of Heart Failure and Non-Pregnant Women With Heart Failure: A Propensity Score Matched Analysis
Analyses
06/21/2022
Analyses
06/21/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/count-and-duration-follow-new-onset-cancer-updated
Count and Duration of Follow up of New-Onset Cancer: An Updated Descriptive Analysis
Analyses
06/23/2022
Analyses
06/23/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/tacrolimus-use-patients-following-liver-or-kidney
Tacrolimus Use in Patients Following Liver or Kidney Transplants: A Descriptive Analysis
Analyses
06/24/2022
Analyses
06/24/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/use-monoclonal-antibodies-mabs-under-emergency-use
Use of Monoclonal Antibodies (mAbs) Under an Emergency Use Authorization (EUA) in Patients with COVID-19 Diagnosis: A Descriptive Analysis
Analyses
06/24/2022
Analyses
06/24/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/seizures-following-gadolinium-based-contrast-agents-exposure
Seizures Following Gadolinium-Based Contrast Agents Exposure: A Self-Controlled Risk Interval Analysis
Analyses
06/29/2022
Analyses
06/29/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/characterization-infants-mother-infant-linkage-table
Characterization of Infants in the Mother-Infant Linkage Table in the Sentinel Distributed Database: A Descriptive Analysis
Analyses
06/30/2022
Analyses
06/30/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-sodium-glucose-co-transporter-2-sglt-2-inhibitor
Utilization of Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitor Drugs: A Descriptive Analysis
Analyses
07/11/2022
Analyses
07/11/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/hospitalization-and-anaphylaxis-following-monoclonal
Hospitalization and Anaphylaxis Following Monoclonal Antibodies (mAb) Use in Patients with COVID-19: A Descriptive Analysis
Analyses
07/14/2022
Analyses
07/14/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-obesity-drugs-descriptive-analysis
Utilization of Obesity Drugs: A Descriptive Analysis
Analyses
08/05/2022
Analyses
08/05/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/differences-covid-19-testing-positivity-hospitalization-and
Differences in COVID-19 Testing, Positivity, Hospitalization, and Mortality by Race and Ethnicity in the Sentinel Distributed Database: A Descriptive Analysis
Analyses
08/19/2022
Analyses
08/19/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/use-monoclonal-antibodies-mabs-under-emergency-use-0
Use of Monoclonal Antibodies (mAbs) Under an Emergency Use Authorization (EUA) in Patients with COVID-19 Diagnosis: An Updated Descriptive Analysis
Analyses
08/24/2022
Analyses
08/24/2022
https://sentinelinitiative.org/news-events/publications-presentations/switching-patterns-mixed-amphetamine-salt-products-fda-s
Switching Patterns of Mixed Amphetamine Salt Products in the FDA’s Sentinel Distributed Database
Publications and Presentations
08/27/2022
Publications and Presentations
08/27/2022
https://sentinelinitiative.org/news-events/publications-presentations/racial-differences-us-covid-19-positivity-hospitalization
Racial Differences in U.S. COVID-19 Positivity, Hospitalization, and Mortality
Spotlight
08/28/2022
Spotlight
08/28/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/comparative-effectiveness-azithromycin-relative-roflumilast
Comparative Effectiveness of Azithromycin Relative to Roflumilast in Individuals With Uncontrolled Chronic Obstructive Pulmonary Disease Despite Triple Inhaled Therapy
Study Protocols & Surveillance Plan
09/01/2022
Study Protocols & Surveillance Plan
09/01/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/fractures-following-leuprolide-acetate-use-multiple-factor
Fractures Following Leuprolide Acetate Use: A Multiple Factor Matched Analysis (A Follow-up to a Previous Analysis)
Analyses
09/16/2022
Analyses
09/16/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-ibrexafungerp-pregnant-patients-descriptive
Utilization of Ibrexafungerp in Pregnant Patients: A Descriptive Analysis in TriNetX
Analyses
10/31/2022
Analyses
10/31/2022
https://sentinelinitiative.org/methods-data-tools/methods/onboarding-commercial-electronic-health-record-ehr-data-partners
Onboarding of Commercial Electronic Health Record (EHR) Data Partners
Methods, Data, & Tools
11/01/2022
Methods, Data, & Tools
11/01/2022
https://sentinelinitiative.org/news-events/publications-presentations/data-driven-automated-classification-algorithms-acute-health
Data-Driven Automated Classification Algorithms for Acute Health Conditions: Applying PheNorm to COVID-19 Disease
Publications and Presentations
11/07/2022
Publications and Presentations
11/07/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/outcome-monitoring-following-zarxio-use-signal
Outcome Monitoring Following Zarxio Use: A Signal Identification Analysis
Analyses
11/10/2022
Analyses
11/10/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/outcome-monitoring-following-ozempic-use-patients-type-2
Outcome Monitoring Following Ozempic Use in Patients with Type 2 Diabetes: A Signal Identification Analysis
Analyses
11/10/2022
Analyses
11/10/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-ixekizumab-pregnant-patients-descriptive
Utilization of Ixekizumab in Pregnant Patients: A Descriptive Analysis
Analyses
11/14/2022
Analyses
11/14/2022
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/exploring-claims-based-definitions-and-characterizing
Exploring Claims-Based Definitions of, and Characterizing Patients with, Respiratory Failure: A Descriptive Analysis
Analyses
01/10/2023
Analyses
01/10/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/identifying-potential-risk-factors-respiratory-failure
Identifying Potential Risk Factors for Respiratory Failure: A Covariate Stratified Analysis
Analyses
01/10/2023
Analyses
01/10/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/characterization-patients-and-encounters-trinetx-live-usa
Characterization of Patients and Encounters in the TriNetX Live USA Network: A Descriptive Analysis
Analyses
01/12/2023
Analyses
01/12/2023
https://sentinelinitiative.org/news-events/publications-presentations/comparative-risk-angioedema-sacubitril-valsartan-versus
Comparative Risk of Angioedema with Sacubitril-Valsartan Versus Renin-Angiotensin-Aldosterone Inhibitors
Publications and Presentations
01/31/2023
Publications and Presentations
01/31/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/cardiovascular-outcomes-following-percutaneous-transluminal
Cardiovascular Outcomes Following Percutaneous Transluminal Septal Myocardial Ablation (PTSMA) Procedures: A Descriptive Analysis
Analyses
02/09/2023
Analyses
02/09/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/cardiovascular-outcomes-following-percutaneous
Cardiovascular Outcomes Following Percutaneous Transluminal Septal Myocardial Ablation (PTSMA) Procedures: An Updated Descriptive Analysis
Analyses
02/09/2023
Analyses
02/09/2023
https://sentinelinitiative.org/methods-data-tools/methods/medical-literature-and-data-cannabis-use
Medical Literature and Data on Cannabis Use
Methods, Data, & Tools
02/23/2023
Methods, Data, & Tools
02/23/2023
https://sentinelinitiative.org/methods-data-tools/sentinel-common-data-model/sentinel-common-components-sas-program-package
Sentinel Common Components SAS® Program Package
Common Data Model
03/01/2023
Common Data Model
03/01/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/congenital-malformations-observed-mother-s-or-linked-infant
Congenital Malformations Observed in the Mother’s or Linked Infant’s Records Following Fingolimod Use During Pregnancy: A Descriptive Analysis
Analyses
03/03/2023
Analyses
03/03/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/congenital-malformations-observed-mother-s-records-following
Congenital Malformations Observed in the Mother’s Records Following Fingolimod Use During Pregnancy: A Descriptive Analysis
Analyses
03/03/2023
Analyses
03/03/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/outcome-monitoring-following-zarxio-use-updated-signal
Outcome Monitoring Following Zarxio Use: An Updated Signal Identification Analysis
Analyses
03/08/2023
Analyses
03/08/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-select-biological-products-descriptive-analysis
Utilization of Select Biological Products: A Descriptive Analysis
Analyses
03/20/2023
Analyses
03/20/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-select-products-migraine-treatment-and
Utilization of Select Products for Migraine Treatment and Prevention: A Descriptive Analysis
Analyses
03/22/2023
Analyses
03/22/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/use-gonadotropin-releasing-hormone-gnrh-agonists-patients
Use of Gonadotropin-Releasing Hormone (GnRH) Agonists in Patients with Gender Dysphoria: A Descriptive Analysis
Analyses
04/13/2023
Analyses
04/13/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/angioedema-following-sacubitrilvalsartan-use-patients-heart
Angioedema Following Sacubitril/Valsartan Use in Patients with Heart Failure: A Propensity Score Analysis
Analyses
04/21/2023
Analyses
04/21/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/angioedema-following-sacubitrilvalsartan-use-patients-0
Angioedema Following Sacubitril/Valsartan Use in Patients with Heart Failure: An Updated Propensity Score Matched Analysis
Analyses
04/21/2023
Analyses
04/21/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/insulin-coding-practices-descriptive-analysis
Insulin Coding Practices: A Descriptive Analysis
Analyses
04/27/2023
Analyses
04/27/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/brand-generic-switching-patterns-among-advair-diskus-users
Brand to Generic Switching Patterns Among Advair Diskus Users with Asthma or Chronic Obstructive Pulmonary Disease (COPD): A Descriptive Analysis
Analyses
05/01/2023
Analyses
05/01/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-and-switching-patterns-inhaled
Utilization and Switching Patterns of Inhaled Corticosteroid/Long Acting Beta Agonist and Advair Diskus in Patients with Asthma or Chronic Obstructive Pulmonary Disease: A Descriptive Analysis
Analyses
05/04/2023
Analyses
05/04/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/ischemic-colitis-following-alosetron-use-descriptive
Ischemic Colitis Following Alosetron Use: A Descriptive Analysis
Analyses
05/24/2023
Analyses
05/24/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/biologics-use-adults-ulcerative-colitis-descriptive-analysis
Biologics Use in Adults with Ulcerative Colitis: A Descriptive Analysis
Analyses
05/24/2023
Analyses
05/24/2023
https://sentinelinitiative.org/studies/drugs/gonadotropin-releasing-hormone-gnrh-agonists
Gonadotropin-Releasing Hormone (GnRH) Agonists & Utilization Characterization
Studies
05/25/2023
Studies
05/25/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/outcome-monitoring-following-erenumab-use-signal
Outcome Monitoring Following Erenumab Use: A Signal Identification Analysis
Analyses
06/22/2023
Analyses
06/22/2023
https://sentinelinitiative.org/news-events/publications-presentations/switching-patterns-immediate-release-forms-generic-mixed
Switching Patterns of Immediate-Release Forms of Generic Mixed Amphetamine Salts Products Among Privately and Publicly Insured Individuals Aged 15-64 Years in the United States, 2013-2019
Publications and Presentations
06/22/2023
Publications and Presentations
06/22/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/renal-cell-carcinoma-following-canagliflozin-use-patients
Renal Cell Carcinoma Following Canagliflozin Use in Patients with Type 2 Diabetes: A Descriptive Analysis
Analyses
07/06/2023
Analyses
07/06/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/alosetron-and-eluxadoline-use-descriptive-analysis
Alosetron and Eluxadoline Use: A Descriptive Analysis
Analyses
07/06/2023
Analyses
07/06/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/dupixent-dupilumab-utilization-patterns-descriptive-analysis
Dupixent (Dupilumab) Utilization Patterns: A Descriptive Analysis
Analyses
07/10/2023
Analyses
07/10/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/prevalence-and-characterization-pharmacogenetic-testing
Prevalence and Characterization of Pharmacogenetic Testing Healthcare Common Procedure Coding System (HCPCS) Procedure Codes in the Mini-Sentinel Distributed Database (MSDD): A Descriptive Analysis
Analyses
07/14/2023
Analyses
07/14/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/baricitinib-or-tocilizumab-use-hospitalized-patients-covid
Baricitinib or Tocilizumab Use in Hospitalized Patients with a COVID-19 Diagnosis: A Descriptive Analysis
Analyses
07/18/2023
Analyses
07/18/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/characterization-cannabis-derived-product-users-trinetx-four
Characterization of Cannabis-Derived Product Users in TriNetX: Four Descriptive Analyses
Analyses
07/19/2023
Analyses
07/19/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-beta-blockers-pediatric-population-descriptive
Utilization of Beta Blockers in the Pediatric Population: A Descriptive Analysis
Analyses
07/19/2023
Analyses
07/19/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-beta-blockers-pediatric-population-updated
Utilization of Beta Blockers in the Pediatric Population: An Updated Descriptive Analysis
Analyses
07/19/2023
Analyses
07/19/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-and-switching-patterns-mixed-amphetamine-salt
Utilization and Switching Patterns of Mixed Amphetamine Salt (MAS) Products in Patients with Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy: A Descriptive Analysis
Analyses
07/25/2023
Analyses
07/25/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/incident-utilization-patterns-obesity-drugs-descriptive
Incident Utilization Patterns of Obesity Drugs: A Descriptive Analysis
Analyses
07/26/2023
Analyses
07/26/2023
https://sentinelinitiative.org/methods-data-tools/methods/effectiveness-fixed-triple-combination-inhaled-corticosteroid-ics-long
Effectiveness of Fixed Triple Combination Inhaled Corticosteroid (ICS), Long-Acting Beta-Agonist (LABA), and Long-Acting Muscarinic Antagonist (LAMA) Products vs. Multiple Inhaler ICS, LABA, LAMA Therapy in Patients With COPD
Methods, Data, & Tools
07/31/2023
Methods, Data, & Tools
07/31/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/incident-utilization-allopurinol-hydralazine-and
Incident Utilization of Allopurinol, Hydralazine, and Propylthiouracil: A Descriptive Analysis
Analyses
07/31/2023
Analyses
07/31/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/bevacizumab-and-other-cancer-medication-use-pregnant
Bevacizumab and Other Cancer Medication Use in Pregnant Patients: A Descriptive Analysis
Analyses
08/04/2023
Analyses
08/04/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/baloxavir-and-oseltamivir-utilization-descriptive-analysis
Baloxavir and Oseltamivir Utilization: A Descriptive Analysis
Analyses
08/18/2023
Analyses
08/18/2023
https://sentinelinitiative.org/news-events/publications-presentations/introducing-colab-evolution-us-canada-international
Introducing CoLab: The Evolution of US-Canada International Collaboration on Drug Safety and Effectiveness
Publications and Presentations
08/25/2023
Publications and Presentations
08/25/2023
https://sentinelinitiative.org/news-events/publications-presentations/characterizing-medication-use-patterns-among-pregnant-and
Characterizing Medication Use Patterns Among Pregnant and Non-Pregnant Patients with COVID-19 in the Sentinel System
Publications and Presentations
08/25/2023
Publications and Presentations
08/25/2023
https://sentinelinitiative.org/news-events/publications-presentations/utilization-beta-blockers-among-pediatric-population-united
Utilization of Beta-blockers Among the Pediatric Population in the United States: A Study in the FDA’s Sentinel System from 2008 to 2022
Publications and Presentations
08/25/2023
Publications and Presentations
08/25/2023
https://sentinelinitiative.org/news-events/publications-presentations/association-between-race-and-covid-19-outcomes-united-states
Association Between Race and COVID-19 Outcomes in the United States (2020-2021)
Publications and Presentations
08/25/2023
Publications and Presentations
08/25/2023
https://sentinelinitiative.org/news-events/publications-presentations/high-dose-dexamethasone-covid-19-not-common-large-us
High Dose Dexamethasone for COVID-19 Not Common in a Large US Hospital Network
Publications and Presentations
08/25/2023
Publications and Presentations
08/25/2023
https://sentinelinitiative.org/news-events/publications-presentations/racial-and-ethnic-differences-treatment-hospitalized-and
Racial and Ethnic Differences in Treatment of Hospitalized and Critical COVID-19, January 2021 - April 2022
Publications and Presentations
08/25/2023
Publications and Presentations
08/25/2023
https://sentinelinitiative.org/news-events/publications-presentations/variation-mother-infant-linkage-rates-jurisdiction-us
Variation in Mother-Infant Linkage Rates by Jurisdiction in U.S. Medicaid Data
Publications and Presentations
08/26/2023
Publications and Presentations
08/26/2023
https://sentinelinitiative.org/news-events/publications-presentations/diversifying-fda-s-sentinel-system-rigorous-quality
Diversifying the FDA’s Sentinel System with Rigorous Quality Inclusion Rules for the U.S. Medicaid Population
Publications and Presentations
08/26/2023
Publications and Presentations
08/26/2023
https://sentinelinitiative.org/news-events/publications-presentations/nlp-detection-mortality-information-publicly-available-data
NLP Detection of Mortality Information from Publicly Available Data Using Deep Learning Modeling
Publications and Presentations
08/26/2023
Publications and Presentations
08/26/2023
https://sentinelinitiative.org/news-events/publications-presentations/utilization-gonadotropin-releasing-hormone-agonist-products
Utilization of Gonadotropin-Releasing Hormone Agonist Products in Adolescents
Publications and Presentations
08/26/2023
Publications and Presentations
08/26/2023
https://sentinelinitiative.org/news-events/publications-presentations/hospitalized-arterial-and-venous-thrombotic-events-patients
Hospitalized Arterial and Venous Thrombotic Events in Patients Diagnosed in the Ambulatory Setting with COVID-19 Compared to Influenza
Publications and Presentations
08/27/2023
Publications and Presentations
08/27/2023
https://sentinelinitiative.org/news-events/publications-presentations/investigating-potential-differences-safety-profiles
Investigating Potential Differences in the Safety Profiles of Biosimilars Relative to Originator Products Using a Tree-Based Scan Statistic
Publications and Presentations
08/27/2023
Publications and Presentations
08/27/2023
https://sentinelinitiative.org/news-events/publications-presentations/principled-approaches-handle-partially-observed-confounder
Principled Approaches to Handle Partially Observed Confounder Data from Electronic Health Records: A Plasmode Simulation Study
Publications and Presentations
08/27/2023
Publications and Presentations
08/27/2023
https://sentinelinitiative.org/news-events/publications-presentations/triple-challenges-small-sample-sizes-both-exposure-and
Triple Challenges – Small Sample Sizes in Both Exposure and Control Groups When Scanning Rare Maternal Outcomes in Signal Identification: A Simulation Study
Publications and Presentations
08/27/2023
Publications and Presentations
08/27/2023
https://sentinelinitiative.org/news-events/publications-presentations/expanding-capabilities-unapproved-cannabis-derived-product
Expanding Capabilities for Unapproved Cannabis-Derived Product Surveillance in the United States, TriNetX, July 1, 2018 – June 30, 2022
Publications and Presentations
08/27/2023
Publications and Presentations
08/27/2023
https://sentinelinitiative.org/news-events/publications-presentations/exploring-use-electronic-health-records-ehr-data-active
Exploring the Use of Electronic Health Records (EHR) Data for Active Safety Surveillance of Epidiolex in PCORnet, July 1, 2018 - July 1, 2022
Publications and Presentations
08/27/2023
Publications and Presentations
08/27/2023
https://sentinelinitiative.org/news-events/publications-presentations/percutaneous-transluminal-septal-myocardial-ablation-and-0
Percutaneous Transluminal Septal Myocardial Ablation and Common Procedural Complications Before and After the Approval of Ablysinol
Publications and Presentations
08/27/2023
Publications and Presentations
08/27/2023
https://sentinelinitiative.org/news-events/publications-presentations/using-real-world-data-evaluate-comparative-effectiveness
Using Real-World Data to Evaluate Comparative Effectiveness Cohorts of Azithromycin Relative to Roflumilast in Individuals with Uncontrolled Chronic Obstructive Pulmonary Disease
Publications and Presentations
08/27/2023
Publications and Presentations
08/27/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-products-development-pregnancy-safety-study
Utilization of Products for the Development of the Pregnancy Safety Study Framework Among Mothers with Live-Birth Deliveries: A Descriptive Analysis
Analyses
09/15/2023
Analyses
09/15/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-products-development-pregnancy-safety-study-0
Utilization of Products for the Development of the Pregnancy Safety Study Framework Among Mothers Linked to Live-Birth Deliveries in the Mother-Infant Linkage Table: A Descriptive Analysis
Analyses
09/15/2023
Analyses
09/15/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-ibrexafungerp-pregnant-patients-descriptive-0
Utilization of Ibrexafungerp in Pregnant Patients: A Descriptive Analysis
Analyses
10/02/2023
Analyses
10/02/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/characterization-use-biologics-and-biosimilars-sentinel
Characterization of Use of Biologics and Biosimilars in the Sentinel Distributed Database: A Descriptive Analysis
Analyses
10/10/2023
Analyses
10/10/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/covid-19-hospitalization-and-severe-covid-19-infection-0
COVID-19 Hospitalization and Severe COVID-19 Infection Following Proton Pump Inhibitor (PPI) Use in Patients with Gastroesophageal Reflux Disease (GERD): An Inverse Probability of Treatment Weighting Analysis
Analyses
10/10/2023
Analyses
10/10/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-dispensing-and-coding-patterns-biologics-and
Utilization, Dispensing, and Coding Patterns of Biologics and Biosimilars in the Sentinel Distributed Database: A Descriptive Analysis
Analyses
10/11/2023
Analyses
10/11/2023
https://sentinelinitiative.org/studies/drugs/aimovig-erenumab-0
Aimovig (Erenumab) & Signal Identification
Studies
10/12/2023
Studies
10/12/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/racial-and-ethnic-differences-covid-19-treatment-and
Racial and Ethnic Differences in COVID-19 Treatment and Mortality in TriNetX: A Descriptive Analysis
Analyses
10/17/2023
Analyses
10/17/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-drugs-approved-risk-evaluation-and-mitigation-0
Utilization of Drugs with Approved Risk Evaluation and Mitigation Strategies (REMS) that Employ Elements to Assure Safe Use (ETASU): A Descriptive Analysis
Analyses
10/18/2023
Analyses
10/18/2023
https://sentinelinitiative.org/news-events/publications-presentations/assessing-risk-intentional-self-harm-montelukast-users-0
Assessing the Risk of Intentional Self-Harm in Montelukast Users: An Observational Study in the Sentinel System Using ICD-10 Coding
Publications and Presentations
10/28/2023
Publications and Presentations
10/28/2023
https://sentinelinitiative.org/news-events/publications-presentations/drug-safety-surveillance-ehr-data-promise-not-yet-fulfilled
Drug Safety Surveillance with EHR Data: A Promise Not Yet Fulfilled
Publications and Presentations
11/13/2023
Publications and Presentations
11/13/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/risk-non-cardiac-congenital-malformations-following
Risk of Non-Cardiac Congenital Malformations Following Armodafinil or Modafinil Use: A Propensity Score Matched Analysis
Analyses
11/13/2023
Analyses
11/13/2023
https://sentinelinitiative.org/methods-data-tools/methods/monitoring-safety-and-effectiveness-covid-19-therapeutics-aim-1-protocol
Monitoring of Safety and Effectiveness of COVID-19 Therapeutics: Aim 1 Protocol Development
Study Protocols & Surveillance Plan
11/17/2023
Study Protocols & Surveillance Plan
11/17/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/characterization-cannabis-derived-product-users-national
Characterization of Cannabis-Derived Product Users in the National Patient-Centered Clinical Research Network (PCORnet): A Descriptive Analysis
Analyses
11/21/2023
Analyses
11/21/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-guselkumab-risankizumab-tildrakizumab-and
Utilization of Guselkumab, Risankizumab, Tildrakizumab, and Brodalumab: An Updated Descriptive Analysis
Analyses
12/07/2023
Analyses
12/07/2023
https://sentinelinitiative.org/news-events/publications-presentations/assessing-risk-intentional-self-harm-montelukast-users
Assessing the Risk of Intentional Self-Harm in Montelukast Users: An Updated Sentinel System Analysis Using ICD-10 Coding
Publications and Presentations
12/08/2023
Publications and Presentations
12/08/2023
https://sentinelinitiative.org/news-events/publications-presentations/data-driven-automated-classification-algorithms-acute-0
Data-Driven Automated Classification Algorithms for Acute Health Conditions: Applying PheNorm to COVID-19 Disease
Publications and Presentations
12/18/2023
Publications and Presentations
12/18/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/lipiodol-ethiodized-oil-and-other-non-oil-based-iodine
Lipiodol (Ethiodized Oil) and Other Non-Oil Based Iodine Imaging Agent Utilization Patterns: A Descriptive Analysis
Analyses
12/22/2023
Analyses
12/22/2023
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/pediatric-use-drug-device-combinations-descriptive-analysis
Pediatric Use of Drug Device Combinations: A Descriptive Analysis
Analyses
12/28/2023
Analyses
12/28/2023
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/bimzelx-bimekizumab-bkzx
Assessment of ARIA Sufficiency: Bimzelx (bimekizumab-bkzx)
Sufficiency Assessments
12/29/2023
Sufficiency Assessments
12/29/2023
https://sentinelinitiative.org/news-events/meetings-workshops-trainings/2024-sentinel-innovation-and-methods-seminar-series
2024 Sentinel Innovation and Methods Seminar Series
Sentinel Initiative Events
01/01/2024
Sentinel Initiative Events
01/01/2024
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/filspari-sparsentan
Assessment of ARIA Sufficiency: Filspari (sparsentan)
Sufficiency Assessments
01/03/2024
Sufficiency Assessments
01/03/2024
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/elfabrio-pegunigalsidase-alfa
Assessment of ARIA Sufficiency: Elfabrio (pegunigalsidase alfa)
Sufficiency Assessments
01/05/2024
Sufficiency Assessments
01/05/2024
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/skyclarys-omaveloxolone
Assessment of ARIA Sufficiency: Skyclarys (omaveloxolone)
Sufficiency Assessments
01/05/2024
Sufficiency Assessments
01/05/2024
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/omvoh-mirikizumab-mrkz
Assessment of ARIA Sufficiency: Omvoh (mirikizumab-mrkz)
Sufficiency Assessments
01/08/2024
Sufficiency Assessments
01/08/2024
https://sentinelinitiative.org/methods-data-tools/methods/covid-19-pandemic-related-changes-healthcare-utilization-among-insured
COVID-19 Pandemic Related Changes in Healthcare Utilization Among Insured Persons in the US and its Impact on Pharmacoepidemiologic Research
Methods, Data, & Tools
01/11/2024
Methods, Data, & Tools
01/11/2024
https://sentinelinitiative.org/studies/drugs/glucagon-peptide-1-receptor-agonists
Glucagon-Like Peptide-1 Receptor Agonists & Intentional Self-Harm
Studies
01/11/2024
Studies
01/11/2024
https://sentinelinitiative.org/news-events/fda-safety-communications-labeling-changes/update-fdas-ongoing-evaluation-reports
Update on FDA's Ongoing Evaluation of Reports of Suicidal Thoughts or Actions in Patients Taking a Certain Type of Medicines Approved for Type 2 Diabetes and Obesity
Regulatory Impact
01/11/2024
Regulatory Impact
01/11/2024
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/hydrochlorothiazide-use-following-labeling-update-include
Hydrochlorothiazide Use Following Labeling Update to Include the Risk of Non-Melanoma Skin Cancer: A Descriptive Analysis
Analyses
01/16/2024
Analyses
01/16/2024
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/sohonos-palovarotene
Assessment of ARIA Sufficiency: Sohonos (palovarotene)
Sufficiency Assessments
01/16/2024
Sufficiency Assessments
01/16/2024
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/fabhalta-iptacopan
Assessment of ARIA Sufficiency: Fabhalta (iptacopan)
Sufficiency Assessments
01/17/2024
Sufficiency Assessments
01/17/2024
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/tzield-teplizumab-mzwv
Assessment of ARIA Sufficiency: Tzield (teplizumab-mzwv)
Sufficiency Assessments
01/17/2024
Sufficiency Assessments
01/17/2024
https://sentinelinitiative.org/studies/devices-radiological-health/characterization-intrauterine-systems-ius-insertion-and-removal
Characterization of Intrauterine Systems (IUS) Insertion and Removal and Oral Contraceptives Dispensings: A Descriptive Analysis
Analyses
01/18/2024
Analyses
01/18/2024
https://sentinelinitiative.org/methods-data-tools/health-outcomes-interest/covid-19-chart-validation-covid-19-severity-algorithm
COVID-19 Chart Validation of COVID-19 Severity Algorithm
Methods, Data, & Tools
01/19/2024
Methods, Data, & Tools
01/19/2024
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/outcome-monitoring-following-baloxavir-use-signal
Outcome Monitoring Following Baloxavir Use: A Signal Identification Analysis
Analyses
01/19/2024
Analyses
01/19/2024
https://sentinelinitiative.org/studies/drugs/xofluza-baloxavir
Xofluza (Baloxavir) & Signal Identification
Studies
01/19/2024
Studies
01/19/2024
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/sezaby-phenobarbital-sodium
Assessment of ARIA Sufficiency: Sezaby (phenobarbital sodium)
Sufficiency Assessments
01/19/2024
Sufficiency Assessments
01/19/2024
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/velsipity-etrasimod
Assessment of ARIA Sufficiency: Velsipity (etrasimod)
Sufficiency Assessments
01/22/2024
Sufficiency Assessments
01/22/2024
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/xacduro-sulbactamdurlobactam
Assessment of ARIA Sufficiency: Xacduro (sulbactam/durlobactam)
Sufficiency Assessments
01/22/2024
Sufficiency Assessments
01/22/2024
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/mixed-amphetamine-salts-immediate-release-tablet-use
Mixed Amphetamine Salts Immediate-Release Tablet Use: A Descriptive Analysis
Analyses
01/24/2024
Analyses
01/24/2024
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/litfulo-ritlecitinib
Assessment of ARIA Sufficiency: Litfulo (ritlecitinib)
Sufficiency Assessments
01/25/2024
Sufficiency Assessments
01/25/2024
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/wainua-eplontersen
Assessment of ARIA Sufficiency: Wainua (eplontersen)
Sufficiency Assessments
01/25/2024
Sufficiency Assessments
01/25/2024
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/zavzpret-zavegepant
Assessment of ARIA Sufficiency: Zavzpret (zavegepant)
Sufficiency Assessments
01/26/2024
Sufficiency Assessments
01/26/2024
https://sentinelinitiative.org/news-events/publications-presentations/smdi-r-package-perform-structural-missing-data
smdi: An R Package to Perform Structural Missing Data Investigations on Partially Observed Confounders in Real-world Evidence Studies
Publications and Presentations
01/31/2024
Publications and Presentations
01/31/2024
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/vanflyta-quizartinib
Assessment of ARIA Sufficiency: Vanflyta (quizartinib)
Sufficiency Assessments
01/31/2024
Sufficiency Assessments
01/31/2024
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/briumvi-ublituximab
Assessment of ARIA Sufficiency: Briumvi (ublituximab)
Sufficiency Assessments
02/02/2024
Sufficiency Assessments
02/02/2024
https://sentinelinitiative.org/methods-data-tools/health-outcomes-interest/coding-trend-analyses-biopsy
Coding Trend Analyses: Biopsy
Methods, Data, & Tools
02/08/2024
Methods, Data, & Tools
02/08/2024
https://sentinelinitiative.org/methods-data-tools/health-outcomes-interest/coding-trend-analyses-crohns-disease
Coding Trend Analyses: Crohn's Disease
Methods, Data, & Tools
02/08/2024
Methods, Data, & Tools
02/08/2024
https://sentinelinitiative.org/methods-data-tools/health-outcomes-interest/coding-trend-analyses-colectomy-colostomy-and-ileostomy
Coding Trend Analyses: Colectomy, Colostomy, and Ileostomy
Methods, Data, & Tools
02/08/2024
Methods, Data, & Tools
02/08/2024
https://sentinelinitiative.org/methods-data-tools/health-outcomes-interest/coding-trend-analyses-diverticulitis-and-colitis
Coding Trend Analyses: Diverticulitis and Colitis
Methods, Data, & Tools
02/08/2024
Methods, Data, & Tools
02/08/2024
https://sentinelinitiative.org/methods-data-tools/health-outcomes-interest/coding-trend-analyses-endoscopy
Coding Trend Analyses: Endoscopy
Methods, Data, & Tools
02/08/2024
Methods, Data, & Tools
02/08/2024
https://sentinelinitiative.org/methods-data-tools/health-outcomes-interest/coding-trend-analyses-ulcerative-colitis
Coding Trend Analyses: Ulcerative Colitis
Methods, Data, & Tools
02/08/2024
Methods, Data, & Tools
02/08/2024
https://sentinelinitiative.org/methods-data-tools/methods/incorporate-range-frequently-used-engineering-features-ehrs-sentinel
Incorporate a Range of Frequently Used Engineering Features from EHRs into the Sentinel Common Data Model in the Sentinel EHR and Claims Linked Data Partner Network
Methods, Data, & Tools
02/09/2024
Methods, Data, & Tools
02/09/2024
https://sentinelinitiative.org/news-events/publications-presentations/risk-arterial-and-venous-thrombotic-events-among-patients
Risk of Arterial and Venous Thrombotic Events Among Patients with COVID-19: A Multi-National Collaboration of Regulatory Agencies from Canada, Europe, and United States
Publications and Presentations
02/10/2024
Publications and Presentations
02/10/2024
https://sentinelinitiative.org/news-events/publications-presentations/process-guide-inferential-studies-using-healthcare-data
Process Guide for Inferential Studies Using Healthcare Data from Routine Clinical Practice to Evaluate Causal Effects of Drugs (PRINCIPLED): Considerations from the FDA Sentinel Innovation Center
Publications and Presentations
02/12/2024
Publications and Presentations
02/12/2024
https://sentinelinitiative.org/methods-data-tools/sentinel-common-data-model/sentinel-common-data-model
Sentinel Common Data Model
Methods, Data, & Tools
02/13/2024
Methods, Data, & Tools
02/13/2024
https://sentinelinitiative.org/methods-data-tools/methods/empirical-application-sentinel-ehr-and-claims-data-partner-network
Empirical Application of the Sentinel EHR and Claims Data Partner Network to Enhance ARIA Sufficient Inferential Requests and Atypical Descriptive Requests (Use Case Package 2)
Methods, Data, & Tools
02/13/2024
Methods, Data, & Tools
02/13/2024
https://sentinelinitiative.org/studies/drugs/dupixent-dupilumab
Dupixent (Dupilumab) & Signal Identification
Studies
02/15/2024
Studies
02/15/2024
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/outcome-monitoring-following-dupilumab-use-signal
Outcome Monitoring Following Dupilumab Use: A Signal Identification Analysis
Analyses
02/15/2024
Analyses
02/15/2024
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/sodium-glucose-cotransporter-2-sglt2-inhibitor-use-patients
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor Use in Patients with Diabetes Mellitus: A Descriptive Analysis
Analyses
02/15/2024
Analyses
02/15/2024
https://sentinelinitiative.org/studies/drugs/olumiant-baricitinib-and-actemra-tocilizumab
Olumiant (Baricitinib) and Actemra (Tocilizumab) & Emergency Use Authorization (EUA) Utilization
Studies
02/15/2024
Studies
02/15/2024
https://sentinelinitiative.org/studies/drugs/pre-pen-plus-benzylpenicilloyl-polylysine
Pre-Pen Plus (Benzylpenicilloyl Polylysine) & Skin Test Antigen Utilization
Studies
02/21/2024
Studies
02/21/2024
https://sentinelinitiative.org/studies/drugs/provigil-modafinil-and-nuvigil-armodafinil-0
Provigil (Modafinil) and Nuvigil (Armodafinil) & Congenital Cardiac and Non-Cardiac Malformations
Studies
02/22/2024
Studies
02/22/2024
https://sentinelinitiative.org/studies/drugs/dupixent-dupilumab-0
Dupixent (Dupilumab) & Indications for Use
Studies
02/23/2024
Studies
02/23/2024
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/counts-and-characteristics-long-acting-injectable
Counts and Characteristics of Long-Acting Injectable Antipsychotic (LAIA) Users: A Descriptive Analysis
Analyses
02/27/2024
Analyses
02/27/2024
https://sentinelinitiative.org/news-events/meetings-workshops-trainings/process-guide-inferential-studies-using-healthcare-data
A PRocess guide for INferential studies using healthcare data from routine ClinIcal Practice to evaLuate causal Effects of Drugs (PRINCIPLED)
Sentinel Initiative Events
02/29/2024
Sentinel Initiative Events
02/29/2024
https://sentinelinitiative.org/studies/drugs/brintellix-vortioxetine-and-brilinta-ticragelor
Brintellix (Vortioxetine) and Brilinta (Ticragelor) & Medication Errors
Studies
02/29/2024
Studies
02/29/2024
https://sentinelinitiative.org/methods-data-tools/methods/maintaining-and-expanding-reach-sentinel-ehr-and-claims-network-di8
Maintaining and Expanding the Reach of the Sentinel EHR and Claims Network (DI8)
Methods, Data, & Tools
03/01/2024
Methods, Data, & Tools
03/01/2024
https://sentinelinitiative.org/studies/drugs/mixed-amphetamine-salts
Mixed Amphetamine Salts & Switching Patterns
Studies
03/01/2024
Studies
03/01/2024
https://sentinelinitiative.org/studies/drugs/rinvoq-upadacitinib
Rinvoq (Upadacitinib) & Acute Myocardial Infarction, Deep Vein Thrombosis, Pulmonary Embolism, and Thrombotic Stroke
Studies
03/01/2024
Studies
03/01/2024
https://sentinelinitiative.org/studies/drugs/glomerular-diseases
Glomerular Diseases & Prevalence
Studies
03/01/2024
Studies
03/01/2024
https://sentinelinitiative.org/studies/drugs/lotronex-alosetron
Lotronex (Alosetron) & Ischemic Colitis
Studies
03/04/2024
Studies
03/04/2024
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/occurrence-stroke-intracranial-hemorrhage-and-bleeding
Occurrence of Stroke, Intracranial Hemorrhage, and Bleeding Outcomes Following Direct Oral Anticoagulant Use in Patients with Atrial Fibrillation: A Descriptive Analysis
Analyses
03/04/2024
Analyses
03/04/2024
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/capture-long-covid-trinetx-descriptive-analysis
Capture of Long COVID in TriNetX: A Descriptive Analysis
Analyses
03/05/2024
Analyses
03/05/2024
https://sentinelinitiative.org/studies/drugs/chronic-conditions
Chronic Conditions & Duration of Follow-Up
Studies
03/06/2024
Studies
03/06/2024
https://sentinelinitiative.org/studies/drugs/covid-19-patients
COVID-19 Patients & Long COVID
Studies
03/07/2024
Studies
03/07/2024
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/ustekinumab-and-comparator-treatment-utilization-and
Ustekinumab and Comparator Treatment Utilization and Pneumonia Outcomes in Patients with Crohn's Disease or Ulcerative Colitis: An Updated Descriptive Analysis
Analyses
03/07/2024
Analyses
03/07/2024
https://sentinelinitiative.org/methods-data-tools/routine-querying-tools/sentinel-routine-querying-system
Sentinel Routine Querying System
Methods, Data, & Tools
03/07/2024
Methods, Data, & Tools
03/07/2024
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/characterization-gimoti-metoclopramide-nasal-spray
Characterization of Gimoti (Metoclopramide Nasal Spray) Dispensing Patterns: A Descriptive Analysis
Analyses
03/08/2024
Analyses
03/08/2024
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/characterization-gimoti-metoclopramide-nasal-spray-0
Characterization of Gimoti (Metoclopramide Nasal Spray) Dispensing Patterns: An Updated Descriptive Analysis
Analyses
03/08/2024
Analyses
03/08/2024
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/racial-and-ethnic-differences-clinical-characteristics
Racial and Ethnic Differences in the Clinical Characteristics of Patients with Various Stages of COVID-19: A Descriptive Analysis
Analyses
03/11/2024
Analyses
03/11/2024
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-and-coding-patterns-long-acting-injectable
Utilization and Coding Patterns of Long-Acting Injectable Antipsychotics (LAIA): A Descriptive Analysis
Analyses
03/11/2024
Analyses
03/11/2024
https://sentinelinitiative.org/studies/drugs/covid-19-outcomes
COVID-19 Patients & Racial and Ethnic Differences
Studies
03/11/2024
Studies
03/11/2024
https://sentinelinitiative.org/studies/drugs/long-acting-injectable-antipsychotics
Long-Acting Injectable Antipsychotics & Mortality
Studies
03/11/2024
Studies
03/11/2024
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/arterial-and-venous-thrombotic-events-patients-covid-19
Arterial and Venous Thrombotic Events in Patients with COVID-19 in Inpatient and Ambulatory Settings: A Descriptive Analysis
Analyses
03/12/2024
Analyses
03/12/2024
https://sentinelinitiative.org/methods-data-tools/routine-querying-tools/sentinel-routine-querying-system-reporting-tool
Sentinel Routine Querying System Reporting Tool
Methods, Data, & Tools
03/13/2024
Methods, Data, & Tools
03/13/2024
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/xenpozyme-olipudase-alfa-rpcp
Assessment of ARIA Sufficiency: Xenpozyme (olipudase alfa-rpcp)
Sufficiency Assessments
03/14/2024
Sufficiency Assessments
03/14/2024
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/rystiggo-rozanolixizumab-noli
Assessment of ARIA Sufficiency: Rystiggo (rozanolixizumab-noli)
Sufficiency Assessments
03/14/2024
Sufficiency Assessments
03/14/2024
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/jesduvroq-daprodustat
Assessment of ARIA Sufficiency: Jesduvroq (daprodustat)
Sufficiency Assessments
03/15/2024
Sufficiency Assessments
03/15/2024
https://sentinelinitiative.org/studies/drugs/statins-tumor-necrosis-factor-tnf-alpha-inhibitors-granulocyte-colony-stimulating
Statins, Tumor Necrosis Factor (TNF) Alpha Inhibitors, Granulocyte Colony Stimulating Factors, Intravenous (IV) Iron, Beta Blockers, and Angiotensin-Converting Enzyme (ACE) Inhibitors & Utilization
Studies
03/15/2024
Studies
03/15/2024
https://sentinelinitiative.org/studies/drugs/angiotensin-converting-enzyme-ace-inhibitors-and-angiotensin-ii-receptor-blockers
Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin II Receptor Blockers (ARBs) & Signal Identification
Studies
03/18/2024
Studies
03/18/2024
https://sentinelinitiative.org/news-events/meetings-workshops-trainings/data-driven-phenotyping-algorithms-acute-health-conditions
Data-driven Phenotyping Algorithms for Acute Health Conditions: Applying PheNorm to COVID-19
Sentinel Initiative Events
03/25/2024
Sentinel Initiative Events
03/25/2024